308 patents currently held
51 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
167 more records may belong here and await a decision; they are not counted.
The next term ends in Nov 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
68
Ending by 2030
Nov 2026
Next term end
148
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2028 · High confidence
Also notable
Ends Aug 2035 · High confidence
Also notable
Ends May 2027 · High confidence
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides
US 8,828,956
Cited by 241 later US patents, top 5% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028. A terminal disclaimer caps this term to an earlier patent's.
Modified Double-Stranded RNA Agents
US 10,233,448
Cited by 45 later US patents, top 5% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2035.
Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
US 7,605,251
Cited by 223 later US patents, top 5% of utility patents granted in 2009 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 19, 2026The maintenance fee for Process for Triphosphate Oligonucleotide Synthesis (US 9,035,041) comes due Nov 19, 2026. Unpaid by May 19, 2027, it lapses early.
- 5 fees due Dec 20 to 30, 2026 · next Dec 20
- 2 fees due Jan 2 to 28, 2027 · next Jan 2
- 6 fees due Feb 6 to 20, 2027 · next Feb 6
- 4 fees due Mar 3 to 15, 2027 · next Mar 3
- 7 fees due May 3 to 28, 2027 · next May 3
- 10 fees due Jun 1 to 24, 2027 · next Jun 1
- 8 fees due Jul 2 to 30, 2027 · next Jul 2
- 8 fees due Aug 2 to 25, 2027 · next Aug 2
- 3 fees due Sep 12 to 24, 2027 · next Sep 12
- 7 fees due Oct 2 to 26, 2027 · next Oct 2
- 1 fee due Nov 5, 2027The maintenance fee for HEPATITIS D VIRUS (HDV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF (US 10,640,770) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
- Oct 28Assignment recorded on 1 record: Bondurant, Lucas and 4 others to Alnylam Pharmaceuticals, Inc. Recorded Oct 28, 2026, executed Mar 12, 2025. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76546, frame 113.
- 5 of the patents on this record were granted since Aug 20, 2026
- 8 terms have ended since Aug 20, 2026
What they patent
The 5 largest of its 148 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 16 in force | to Sep 2032 |
| Biodegradable Lipids for the Delivery of Active Agents | 15 in force | to Dec 2032 |
| Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | 11 in force | to Dec 2029 |
| Modified Double-Stranded RNA Agents | 10 in force | to Aug 2035 |
| Complement Component C5 Irna Compositions and Methods of Use Thereof | 6 in force | to Mar 2034 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,658,782 | Compositions And Methods For Inhibiting Expression Of Factor V In force · Medium confidence | In force | Medium confidence | |
| US 7,985,581 | Multiple RNA Polymerase III Promoter Expression Constructs In force · High confidence | In force | High confidence | |
| US 7,579,451 | Oligonucleotides Comprising a Modified or Non-Natural Nucleobase In force · High confidence | In force | High confidence | |
| US 7,605,251 | Compositions and Methods for Inhibiting Expression of the PCSK9 Gene In force · High confidence | In force | High confidence | |
| US 8,809,292 | Compositions And Methods For Inhibiting Expression Of The PCSK9 Gene In force · High confidence | In force | High confidence | |
| US 9,260,718 | Compositions and Methods for Inhibiting Expression of the PCSK9 Gene In force · High confidence | In force | High confidence | |
| US 9,822,365 | Compositions and Methods for Inhibiting Expression of the PCSK9 Gene In force · Medium confidence | In force | Medium confidence | |
| US 10,501,742 | Compositions and Methods for Inhibiting Expression of the PCSK9 Gene In force · Low confidence | In force | Low confidence | |
| US 7,846,908 | Rnai Modulation of Tgf-Beta and Therapeutic Uses Thereof In force · High confidence | In force | High confidence | |
| US 8,124,752 | Compositions and Methods for Inhibiting Expression of the Myc Gene In force · High confidence | In force | High confidence |
Also on record, not counted in the 308: 51 patents in force now held by others · 144 patents ended · 190 applications pending · 336 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.